Pharvaris CCO sells 10,000 shares in planned trade

Rhea-AI Filing Summary

Pharvaris N.V. Chief Commercial Officer Wim Souverijns sold 10,000 shares of Common Stock in an open-market transaction at a weighted average price of $29.9163 per share. The sale was executed on May 15, 2026 under a pre-arranged Rule 10b5-1 trading plan, and Souverijns held 45,111 shares after the transaction.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Souverijns Wim

Role Chief Commercial Officer

Sold 10,000 shs ($299K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$29.9163	$299K

Holdings After Transaction: Common Stock — 45,111 shares (Direct)

Footnotes (2)

1. F1. This is a scheduled sale from 10b5-1 trading plan.
2. F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $29.725 to $30.08. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 10,000 shares Weighted average sale price: $29.9163 per share Post-transaction holdings: 45,111 shares +1 more

4 metrics

Shares sold 10,000 shares Open-market sale on May 15, 2026

Weighted average sale price $29.9163 per share Common Stock sale on May 15, 2026

Post-transaction holdings 45,111 shares Common Stock held directly after sale

Price range of sales $29.725 to $30.08 Multiple transactions included in weighted average

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, restricted stock units

3 terms

Rule 10b5-1 trading plan regulatory

"The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date..."

restricted stock units financial

"The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pharvaris (PHVS) report for Wim Souverijns?

Pharvaris reported that Chief Commercial Officer Wim Souverijns sold 10,000 shares of Common Stock. The transaction occurred on May 15, 2026 as an open-market sale executed under a pre-arranged Rule 10b5-1 trading plan.

At what price did the Pharvaris (PHVS) insider shares sell in this Form 4?

The reported sale used a weighted average price of $29.9163 per share. Actual trades occurred in multiple transactions, with individual sale prices ranging from $29.725 to $30.08 on the reported date under a Rule 10b5-1 trading plan.

How many Pharvaris (PHVS) shares does Wim Souverijns hold after this Form 4 sale?

Following the reported transaction, Wim Souverijns held 45,111 shares of Pharvaris Common Stock directly. This post-transaction holding reflects the remaining position after selling 10,000 shares in the open market under a Rule 10b5-1 trading plan.

Was the Pharvaris (PHVS) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sale by Wim Souverijns was a scheduled transaction executed under a Rule 10b5-1 trading plan. Such plans pre-arrange trade timing and size, reducing the significance of short-term market timing decisions.

What does the weighted average sale price mean in the Pharvaris (PHVS) Form 4?

The weighted average sale price of $29.9163 represents the combined average for multiple trades executed that day. Individual transactions occurred between $29.725 and $30.08, and the insider offered to provide detailed breakdowns of shares sold at each price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 06:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Souverijns Wim

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		S(1)		10,000	D	$29.9163(2)	45,111	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This is a scheduled sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $29.725 to $30.08. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

	/s/ Marnus Nel, Attorney-in-Fact for Wim Souverijins	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)